Laham, Y., Ringelstein-Harlev, S., Kurnik, D., Fineman, R., Yehudai-Ofir, D., Bonstein, L., . . . Beyar-Katz, O. High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies. Ferrata Storti Foundation.
Chicago Style (17th ed.) CitationLaham, Yousef, et al. High-dose Intravenous Immunoglobulin May Be an Efficient Treatment Option for Patients with Late-onset High-grade Immune Effector Cell-associated Hematotoxicity Refractory to Standard Therapies. Ferrata Storti Foundation.
MLA (9th ed.) CitationLaham, Yousef, et al. High-dose Intravenous Immunoglobulin May Be an Efficient Treatment Option for Patients with Late-onset High-grade Immune Effector Cell-associated Hematotoxicity Refractory to Standard Therapies. Ferrata Storti Foundation.